Jazz Pharma to sell women's health business for $95M

Jazz Pharmaceuticals will sell its women's heath business to specialty pharmaceutical company Meda for $95 million in cash. Jazz, which has an office in Palo Alto (NASDAQ:JAZZ) said in the release that the sale involves six products: Elestrin, Gastrocrom, Natelle One, AVC, Gesticare DHA and Urelle.

Jazz to buy EUSA Pharma for $650M cash

Jazz Pharmaceuticals plc said Thursday it is planning to acquire a private specialty pharmaceutical company, EUSA Pharma Inc., which has headquarters in the United States and the United Kingdom. Jazz, which has an office in Palo Alto (NASDAQ:JAZZ), is paying $650 million in cash, plus a potential milestone payment of $50 million in cash based on EUSA's lead product meeting an undisclosed, specified U.S. net sales target in 2013. The product is a life-saving treatment for a form of leukemia that primarily affects children.

Jazz closes up more than 9% on brighter profit outlook

Jazz Pharmaceuticals Inc.'s stock closed Friday at $45.39 per share, up 9.49 percent.
The jump comes following the Palo Alto-based specialty pharmaceutical company (NASDAQ:JAZZ) saying Thursday it is expecting a larger profit in 2012, following its purchase of Azur Pharma Ltd. The deal witth Azur is expected to close the week of Jan. 16.
It also said sales of its narcolepsy drug, Xyrem, have done well.

NeurogesX chief medical officer resigns, heads to Jazz Pharma

Dr. Jeffrey Tobias, chief medical officer of pain drug developer NeurogesX Inc. since 2005, will resign effective Oct. 16
It is the second high-level departure this year for San Mateo-based NeurogesX (NASDAQ: NGSX). President and CEO Anthony DiTonno said in April that he would retire by the end of the year.

Jazz Pharma Q1 profit jumps to $21.8M

Jazz Pharmaceuticals Inc. on Tuesday reported first quarter net income of $21.8 million, or 48 cents a share, compared to $1.5 million, or 4 cents a share in the same period last year.
Palo Alto-based Jazz (NASDAQ:JAZZ) reported revenue of $50.9 million, up from the year-ago quarter's $35.2 million.

In time of crisis, Threshold finds strength in life sciences community

With the sudden death April 20 of Dr. John Curd, the Redwood City biotech company’s president and chief medical officer, Threshold (NASDAQ: THLD) was faced with a crisis no company wants to experience. But as news of Curd’s death spread, the Redwood City company was overwhelmed with doctors and others in the biomedical community volunteering to serve as interim chief medical officer.

Jazz Pharma earns $24M in Q4, $33M in 2010

Jazz Pharmaceuticals Inc. earned $24.5 million in the December quarter and $32.8 million in 2010.
The Palo Alto company (NASDAQ: JAZZ) had revenue of $53.4 million in the fourth quarter, up from revenue of $38.3 million a year earlier in the same quarter, when it earned $5.7 million.